Your browser doesn't support javascript.
loading
In Vitro and Cellular Probes to Study PARP Enzyme Target Engagement.
Wigle, Tim J; Blackwell, Danielle J; Schenkel, Laurie B; Ren, Yue; Church, W David; Desai, Hetvi J; Swinger, Kerren K; Santospago, Andrew G; Majer, Christina R; Lu, Alvin Z; Niepel, Mario; Perl, Nicholas R; Vasbinder, Melissa M; Keilhack, Heike; Kuntz, Kevin W.
Afiliação
  • Wigle TJ; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA. Electronic address: twigle@ribontx.com.
  • Blackwell DJ; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Schenkel LB; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Ren Y; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Church WD; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Desai HJ; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Swinger KK; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Santospago AG; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Majer CR; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Lu AZ; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Niepel M; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Perl NR; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Vasbinder MM; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Keilhack H; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
  • Kuntz KW; Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
Cell Chem Biol ; 27(7): 877-887.e14, 2020 07 16.
Article em En | MEDLINE | ID: mdl-32679093
ABSTRACT
Poly(ADP-ribose) polymerase (PARP) enzymes use nicotinamide adenine dinucleotide (NAD+) to modify up to seven different amino acids with a single mono(ADP-ribose) unit (MARylation deposited by PARP monoenzymes) or branched poly(ADP-ribose) polymers (PARylation deposited by PARP polyenzymes). To enable the development of tool compounds for PARP monoenzymes and polyenzymes, we have developed active site probes for use in in vitro and cellular biophysical assays to characterize active site-directed inhibitors that compete for NAD+ binding. These assays are agnostic of the protein substrate for each PARP, overcoming a general lack of knowledge around the substrates for these enzymes. The in vitro assays use less enzyme than previously described activity assays, enabling discrimination of inhibitor potencies in the single-digit nanomolar range, and the cell-based assays can differentiate compounds with sub-nanomolar potencies and measure inhibitor residence time in live cells.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Poli(ADP-Ribose) Polimerases / Corantes Fluorescentes / Inibidores de Poli(ADP-Ribose) Polimerases Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Poli(ADP-Ribose) Polimerases / Corantes Fluorescentes / Inibidores de Poli(ADP-Ribose) Polimerases Idioma: En Ano de publicação: 2020 Tipo de documento: Article